ERT is innovating clinical trial virtualization through its partnership with Inofab Health, makers of Spirohome, the world’s first ultrasonic personal spirometer.
“This partnership enables ERT to further drive innovation in trial virtualization and supports our commitment to offering the best range of trial continuity options, specifically for sponsors developing new respiratory disease treatments.” - Achim Schülke, EVP Respiratory, ERT.
PHILADELPHIA (PRWEB) June 25, 2020
ERT, the global leader in clinical endpoints data collection, today announced a strategic partnership with Inofab Health, a healthcare technology company designing and developing ultrasonic spirometry technology for in-clinic and at-home use. Through the partnership, ERT expands its portfolio of innovative virtual trial solutions to give clinical trial sponsors and contract research organizations (CROs) multiple options for continuing their life-saving research throughout the pandemic and beyond.
Sponsors are looking for reliable data collection methods that enable the continuation of important clinical trials and ensure the safety of clinical trial patients, without requiring them to attend investigative site appointments. ERT is meeting this need with a suite of innovative virtual trial solutions that capture high-quality data from the comfort of patients’ homes.
“We chose to partner with Inofab based on their proven capabilities in meeting respiratory patients’ healthcare needs and their award-winning ultrasonic spirometer, Spirohome,” said Achim Schülke, Executive Vice President of Respiratory Solutions at ERT. “This partnership enables ERT to further drive innovation in trial virtualization and supports our commitment to offering the best range of trial continuity options, specifically for sponsors developing new respiratory disease treatments.”
Since patients with lung disease are at higher risk for developing more serious complications from the COVID-19 illness, many are likely to avoid clinics or investigative sites to minimize their exposure risk. Together, ERT and Inofab will continue to develop patient-friendly, easy to use solutions enabling at-home, patient-administered testing of the lung, supporting patient comfort and safety while ensuring high-quality data collection to keep respiratory trials on track.
“We’re pleased to partner with ERT and to leverage their extensive experience in delivering the important safety and efficacy data sponsors need when developing new respiratory treatments,” said Kerem Yasar, Chief Technology Officer and Co-Founder of Inofab Health. “Spirohome plays a critical role for endpoint data collection and we’re excited to work with ERT in delivering virtual trial solutions that help clinical trial sponsors continue developing new treatments for the millions of patients living with respiratory disease.”
For more information on ERT’s suite of virtual trial solutions, visit virtualtrials.ert.com.
About ERT
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2019, 75% of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs, and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.
For more information, go to ert.com or follow us on LinkedIn and Twitter.
About Inofab Health
Inofab Health offers revolutionizing respiratory care solutions for home and professional use with a human-centric approach and cutting-edge technology. It provides a functional respiratory care management platform along with ultrasonic personal & clinic spirometers and connected inhaler attachments. Inofab Health alerts any declines in lung health, allowing quick intervention against symptom onset and prevents unnecessary hospitalisations.
For further information see https://Inofab.health.